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Abstract The relative roles of various autoantibodies against
IL-17-type cytokines in susceptibility to chronic mucocutane-
ous candidiasis (CMC) in patients with autoimmune
polyendocrinopathy-candidiasis-ectodermal dystrophy
(APECED) remain poorly defined. The purpose of this longi-
tudinal study was to analyze the relationship between the
occurrence of mucocutaneous candidiasis and levels of anti-
IL-17A, anti-IL-17F and anti-IL-22 autoantibodies. We stud-
ied six APECED patients from four families with various
disease manifestations. Clinical data were collected during
regular follow-up. Anti-endocrine organ antibody levels and
clinical chemistry and immunology parameters were deter-
mined in routine laboratory assays on freshly isolated serum.
Levels of autoantibodies against IL-17A, IL-17F, IL-22,
IFN-α, IFN-ω and TNF-α, and cytokine release by Candida-
exposed blood cells were determined by ELISA. Mutations
were analyzed by sequencing genomic DNA. Four patients
carried the germline c.769C>T homozygous nonsense muta-
tion, which results in R257X truncation of the AIRE protein,
and two patients from the same family were compound het-
erozygous for the c.769C>T/c.1344delC mutation. We found
persistently high levels of antibodies against IL-17A in the
serum samples of one patient presenting CMC since infancy
and low or undetectable anti-IL-17A antibody levels in the
sera of five patients with no candidiasis or without severe
candidiasis. By contrast, levels of autoantibodies against IL-
17F and IL-22 were higher in all patients than in healthy
controls. Release of IL-17-type cytokines by Candida-
exposed blood mononuclear cells was low or negligible in
all patients tested. We suggest that anti-IL-17A antibodies
may play an important role in the predisposition to candidiasis
of APECED patients. However, the lack of severe CMC in
APECED patients with high levels of IL-17F and anti-IL-22
autoantibodies clearly calls into question the role of these
antibodies as the principal cause of cutaneous and mucosal
candidiasis in at least someAPECED patients. These data also
suggest that the impaired release of IL-17-type cytokines by
blood cells may be an element of the immunopathology of
CMC in APECED patients.
Keywords APECED . IL-17 . IL-22 . chronic
mucocutaneous candidiasis
Introduction
Chronic mucocutaneous candidiasis (CMC) associated with
hypoparathyroidism was first reported by Thorpe and
Handley in 1929 [34]. This condition was commonly referred
to as Schmidt’s syndrome, after the German pathologist who
studied autoimmunity to more than one endocrine organ [9].
Autoimmune polyendocrine syndrome associated with CMC
is a rare autosomal recessive disease and is also referred to as
autoimmune polyendocrinopathy-candidiasis-ectodermal
dystrophy (APECED) [10, 22]. APECED is caused by a
loss-of-function mutation of the autoimmune regulator gene
(AIRE), resulting in the production of a mutant AIRE protein,
which allows autoreactive T cells to escape negative selection
in the thymus, leading to autoimmunity to various endocrine
organs and the production of autoantibodies against self-
antigens and various cytokines [10–12, 17–19, 25, 26]. The
diagnosis of APECED is based on the presence of at least two
of three major clinical manifestations: CMC, primary hypo-
parathyroidism and primary adrenocortical insufficiency
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(Addison’s disease) [2, 10, 16, 25]. In most cases, signs and
symptoms of the disease appear in infancy or childhood and
affected patients typically develop three to seven different
disease manifestations. In addition to the major criteria, minor
disease components are also common [3, 4, 25, 38]. These
signs and the major components of disease often develop in a
particular chronological order. CMC commonly begins before
the age of 5 years, followed (usually years later) by autoim-
mune hypoparathyroidism before the age of 10 years and
adrenal insufficiency before the age of 15 years [2, 10, 20].
The earliest and most common clinical manifestation in
early childhood is CMC, which is particularly common in
patients carrying the Finnish homozygous allele R257X [11,
12]. Oral candidiasis frequently develops during the first year
of life, followed by the involvement of the skin and nails, with
various degrees of severity [10, 11, 17]. Chronic oral candi-
diasis may lead to leukoplakia and may increase the risk of
squamous epithelial carcinoma. In several cases, carcinoma
has been reported in association with mucocutaneous candi-
diasis of the oropharyngeal cavity and the esophagus, sug-
gesting that persistent mucosal candidiasis may be carcino-
genic in the absence of other risk factors [30, 31, 37]. Candi-
diasis of the nails results in thickening and discoloration,
paronychia and nail loss. Candida infection may cause super-
ficial mucous membrane lesions in the esophagus, serious
inflammation with strictures, painful swallowing, retrosternal
pain and a sensation of food becoming stuck in the chest.
Female patients typically develop chronic vulvovaginitis. Hy-
poparathyroidism generally occurs within 10 years of the
onset of candidiasis, but it may manifest at any time in
adulthood. Adrenocortical failure generally occurs after the
onset of candidiasis and/or hypoparathyroidism, with a peak
incidence between the ages of four and 12 years, but hormone
levels may fluctuate for years [20]. Adrenal insufficiency is
preceded by the production of anti-21-hydroxylase antibodies.
Other endocrine signs include ovarian failure, diabetes
mellitus type 1, testicular failure, autoimmune thyroiditis and
hypophysitis [19, 20, 25, 38]. APECED may be associated
with gastrointestinal signs, such as autoimmune gastritis, hep-
atitis and malabsorption syndromes [10]. Ectodermal dystro-
phy may include dental enamel hypoplasia, keratopathy, vit-
iligo, alopecia, nail pitting and tympanic membrane calcifica-
tions [4, 38]. Vitiligo may develop in the first month of life and
its extent is highly variable, from isolated spots to coverage of
almost the entire body surface [4].
We describe here the longitudinal observation of six
APECED patients with various clinical signs and laboratory
findings. Our findings suggest that anti-IL-17A, but not anti-
IL-17F or anti-IL-22 antibodies are the key factors determin-
ing susceptibility to candidiasis in APECED patients. We also
suggest that there may not be a strong chronological relation-
ship between the production of autoantibodies and the devel-
opment of clinical signs of APECED. Finally, we present data
suggesting that the release of IL-17-type cytokines by the
Candida-exposed blood mononuclear cells of APECED pa-
tients may be impaired.
Materials and Methods
Patient 1
This 10-year-old boy had nail dystrophy, dental enamel hy-
poplasia and nail pitting from the age of 3.5 years. At the age
of 4 years, he presented chickenpox and developed alopecia
totalis, involving the scalp, eyelashes and eyebrows, which
has persisted ever since (Fig. 1b). Routine laboratory tests
showed persistent hyperphosphatemia and high thyroid-
stimulating hormone (TSH) levels, but serum calcium con-
centration and liver enzyme activities were normal (Table I).
The patient has not had mucosal or skin candidiasis. An
adrenal cortex antibody assay showed persistent weak posi-
tivity without signs of autoimmune adrenal insufficiency.
Patient 2
This 7-year-old girl (the sister of Patient 1; Fig. 1a) developed
muscle cramps, recurrent upper respiratory tract infections and
oral and nail candidiasis caused by Candida albicans at
18 months of age. Calcium and vitamin D supplementation
was initiated. At 4 years of age, blood tests showed low serum
parathormone (PTH) concentration, hyperphosphatemia,
hypergammaglobulinemia and high levels of liver enzymes
(Table I). At the age of 5 years, P2 had a low serum cortisol
concentration and developed iron deficiency with hypochro-
mic microcytic anemia (Table I). Laboratory and genetic tests
excluded celiac disease and DiGeorge syndrome. This patient
had organ-specific autoantibodies against liver-kidney micro-
somal enzymes and the adrenal cortex (Table I). She was
treated with anti-fungal agents (borax-glycerin, nystatin,
fluconazole), parenteral and oral calcium and vitamin D de-
rivatives from early childhood. At 5 years of age, given the
persistence of hypertransaminasemia and treatment-resistant
candidiasis, we initiated intravenous immunoglobulin therapy
(IVIG), at a dose of 560 mg/kg monthly. One week after the
first session of IVIG treatment, oral candidiasis had improved,
and the patient remained symptom-free for 2 weeks. In the
following month, before IVIG treatment, laboratory tests
showed a decrease in liver enzyme levels and a normal serum
calcium concentration. One year after the first IVIG infusion,
the patient presented with fever once or twice per week (Tmax:
39.3 °C), followed by an urticarial rash on her arms and legs.
Symptoms ceased spontaneously after 12 to 24 h. Laboratory
tests showed high levels of liver enzymes (GOT 78 U/l, GPT
54 U/l) and C-reactive protein (16.4 mg/l; normal: <5 mg/l), a
high white blood cell count (12.49 G/l; normal range: 4.5–
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11.5 G/l) and granulocytosis (9.14 G/l; normal range: 1.9–
7.7 G/l). IgG and IgM levels were 38.4 g/l and 2.35 g/l,
respectively, and serum protein electrophoresis excluded
monoclonal gammopathy. Serological tests for Epstein-Barr
virus, cytomegalovirus, hepatitis A-, B-, C-, and E virus
infections were negative. Recurrent maculopapular,
morbilliform and urticarial erythemawith fever have also been
reported in other cases of APECED, with skin biopsy in some
cases revealing lymphoplasmacytic vasculitis [38]. Liver pro-
tection therapy (silimarin, vitamin B complex) and local anti-
fungal treatment with borax-glycerin and nystatin were initi-
ated. Four weeks after the cessation of IVIG, serum Ig and
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Fig. 1 Pedigrees, clinical features and AIRE mutation of APECED
patients. a Pedigree and AIRE sequence variants of Patients 1 and 2.
Patients with APECED (II/1 and II/2) are homozygous for the c.769C>
T nonsense mutation predicting a stop codon in the AIRE gene, whereas
the asymptomatic parents (I/1 and I/2), and sister (II/3) are heterozygous.
The position of the nucleotide change in AIRE is circled and the codons
affected by the mutation are underlined. b Alopecia totalis of Patient 1
(left) and nail candidiasis of Patient 2 (right) carrying the same c.769C>T
homozygous nonsense mutation. c Pedigree and mutant AIRE sequences
of Patient 3 (II/4). This patient was homozygous for the c.769C>T
nonsense mutation of AIRE. The position of the mutated nucleotides is
circledand the codons affected by the mutation are underlined. One of the
sisters (II/3) of Patient 3 died of adrenal failure at the age of 10 years and
no DNA sample was available for genetic testing. d Schematic represen-
tation of the c.769C>T (R257X) mutation (black squares) and a silent
sequence variant (c.681C>T; p.G227G; green ovals) in the family of
Patient 3 (see also c). The mother (I/2) and two children (II/1 and II/2)
are heterozygous for both the pathologic and silent mutations, whereas
the father is heterozygous (I/1) and Patient 3 (II/4) is homozygous for the
disease-causing mutation. e Pedigree and AIREmutation of Patient 6
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liver enzyme levels gradually decreased, but the oral candidi-
asis remained resistant to local and oral treatment. Patients 1
and 2 were from the same family and had the same AIRE
mutation, but had completely different clinical phenotypes.
Patient 1 developed alopecia totalis after contracting
chickenpox. He also has nail dystrophy without Candida
infection. Patient 2 has been suffering from CMC since the
age of 18 months. She also developed impaired liver function
at the age of 4 years (Table I).
Patient 3
This 5-year-old boywas first seen at our department at 3 weeks
of age. His sister was diagnosed with APECED at 2 years of
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age, she had had severe CMC since early infancy, recurrent
respiratory infections, adrenal and parathyroid insufficiency.
She died from adrenal failure during an episode of acute
bacterial infection and dehydration (Fig. 1c).
Based on the family history and in response to parental
requests, we performed molecular genetic analysis and regular
follow-up for this boy. From the ages of 12 to 36 months he
had mild persistent hyperphosphatemia (Table I). Determina-
tions of serum immunoglobulin isotypes showed low IgA and
high IgG levels (Table I). Weakly positive results were obtain-
ed only once for anti-adrenal and anti-islet cell organ-specific
autoantibodies. This 5-year-old patient has no clinical signs of
disease, but has produced high levels of anti-cytokine autoan-
tibodies since infancy (Fig. 2).
Endocrine organ involvement differed considerably be-
tween these three APECED patients. Patient 1 had no endo-
crine organ deficiency or electrolyte imbalance, or other signs
of autoimmune disease, despite the persistent detection of
anti-adrenal autoantibodies. Patient 2 has hypoparathyreosis
with low PTH concentrat ion, hypocalcemia and
hyperphosphatemia. She has high liver enzyme and serum
IgG and M levels. Patient 3 showed subclinical signs of
hypoparathyreosis, with slightly high phosphate levels and
high levels of IgG. He had a transiently low cortisol concen-
tration, with no anti-adrenal autoantibodies. The GAD anti-
body was detected during a transitional period.
Patient 4
This 27-year-old man had recurrent sinusitis and allergic
atopic dermatitis from childhood. He developed hypoparathy-
roidism and hypocalcemia at the age of 9.5 years and adrenal
hypofunction at 11 years of age. His parents are healthy and
his only sibling (Patient 5) also has APECED. At the age of
14 years, he was diagnosed with corneal degeneration and
cataracts and subsequently underwent several ophthalmolog-
ical operations and corneal abrasion. He has suffered from
recurrent non-purulent conjunctivitis and atopic allergic asth-
ma. This patient has not had chronic mucosal or skin candi-
diasis; he presented with intermittent angular cheilitis since
the age of 21 years, with no microbiological confirmation of a
candidial etiology. He occasionally has palpitations and weak-
ness, and cardiological examination revealed mitral prolapse
with mild regurgitation. He has been on regular calcium and
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active vitamin D supplementation, with hydrocortisone re-
placement since the development of endocrinopathy during
childhood.
Patient 5
This 22-year-old man (the brother of patient 4) presented with
weakness of the extremities and muscle cramps associated
with a severe episode of viral gastrointestinal infection at the
age of 11 years. Chvostek’s sign was positive; laboratory tests
showed hypocalcemia and very low parathormone levels and
the patient was diagnosed with hypoparathyreosis (Table I).
At the age of 17 years, he developed isolated nail candidiasis
of the right thumb. Candidial infection recurred several
times at this anatomic location, but the patient has no muco-
sal, cutaneous or nail candidiasis at any other site. At the age
of 21 years, this patient presented with persistent and progres-
sive weight loss, and laboratory tests revealed hypoadrenia,
with high levels of ACTH and lower levels of cortisol
(Table I). His endocrine status has stabilized on substitution
therapy.
Patient 6
This 9-year-old girl presented with recurrent upper respiratory
tract infections and purulent otitis media and was frequently
treated with antibiotics between the ages of 18 months and
5 years. Bilateral paracentesis was performed several times
and, at the age of 5 years, a tube (grommet) was implanted,
resulting in significant clinical improvement. The patient’s
speech and communication development and social adapta-
tion were delayed and audiology analysis revealedmixed-type
hearing impairment necessitating the use of a hearing aid. At
the age of 8 years, this patient presented with muscle cramps
and tetany in association with an acute episode of viral gas-
trointestinal infection. Laboratory tests revealed hypocalcemia
and hypoparathyreosis. Until the age of 3 years, P6 presented
short episodes of mild soor oris and vulvovaginitis about once
per year, which have not occurred since.
Analysis of AIRE Mutations
Genomic DNA was sequenced by amplifying the exons and
flanking intron regions of AIRE by PCR. Amplicons were
sequenced with the Big Dye Terminator cycle sequencing kit
(Applied Biosystems, Foster City, CA, USA) and analyzed
with an ABI PRISM 3130 capillary sequencer (Applied
Biosystems). Sequence variations were described with respect
to a reference sequence (GenBank accession No.
ENST00000291582) for AIRE cDNA, in which the c.1 posi-
tion corresponds to the A of the ATG translation initiation
codon. Mutations are designated as recommended by den
Dunnen and Antonarakis [7].Ta
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Serum Samples
Blood was taken under aseptic conditions and serum was
isolated by centrifuging blood at 2,500 rpm (550×g) for
10 min at room temperature. Aliquots of the samples from the
patients and healthy controls were frozen at −20 °C until use.
Routine Laboratory Assays
Anti-endocrine organ antibody levels, clinical chemistry and
immunology parameters were determined by routine labora-
tory assays with freshly isolated serum.
Anti-Cytokine Antibody Assays
Levels of serum autoantibodies binding to IL-17A, IL-17F,
IL-22, IFN-α and IFN-ωwere determined by ELISA. Briefly,
cytokine samples (IL-17A, IL-17F and IL-22 from Peprotech,
EC, London; INF-α and IFN-ω from Rocky Hill, NJ, USA)
were diluted in PBS (0.1 μg/ml). We then coated Nunc
MaxiSorp immunosorbent 96-well flat-bottomed plates with
100 μl of cytokine suspension/well and incubated the plates
overnight at 4 °C. The supernatant was removed and the
nonspecific binding sites were blocked by incubation for 2 h
at room temperature with 100 μl of blocking buffer (0.1 %
Tween-20, 3 % bovine serum albumin in PBS) per well. The
plates were then washed four times with washing buffer (0.1 %
Tween-20 in PBS). Serum samples were diluted 1:1000 in
blocking buffer, and 100 μl of the dilutions was added to wells
and incubated for 1 h at room temperature. The plates were
washed four more times. Alkaline phosphatase-conjugated goat
anti-human IgG was diluted 1:10000 in antibody buffer, and
100 μl was added to each well. The plates were then incubated
for 1 h at room temperature. The plates were washed five times
with washing buffer and antibody binding was visualized by
adding a solution of the substrate, p-nitrophenol, according to
the manufacturer’s protocol and determining absorbance at
405 nm, with a Multiskan EX photometer (Thermo Scientific,
Shanghai, China), after incubation in the dark for 4.5 min.
Candida
C. albicans (ATCC 10231) was maintained on Sabouraud
dextrose agar at 4 °C and stationary-phase cultures were
prepared by inoculating 2 ml of DMEM. Heat-killed Candida
was prepared by inoculating 5 ml SalSol (TEVA, Debrecen,
Hungary) withCandidaand incubating the culture at 56 °C for
60 min. The Candida suspension was then centrifuged at
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Fig. 2 Autoantibodies against IL-17A, IL-17F and IL-22 in the sera of
APECED patients. In Patients 1, 3, 4, 5, and 6 (a and d–f) with no
candidiasis or with mild and transient CMC, levels of anti-IL-17A auto-
antibodies, as measured by OD values, were low or undetectable, con-
trasting with the persistently high levels of anti-IL-17A antibodies in
Patient 2 (b), who presented with severe and persistent CMC from the
age of 18 months. Except for P2, anti-IL-22 antibody OD values were
higher, comparing to antibodies to other cytokines in all patients (a–f). We
obtained similarly high OD values for anti-IL-17F antibodies in the sera
of APS-1 patients with severe oral and therapy-resistant nail candidiasis
and intermittent angular cheilitis (b), patients with mild intermittent
angular cheilitis or mild, isolated nail candidiasis (d, e) and patients
without candidiasis (a, c, f). OD values for anti-IL-17F autoantibodies
were higher than anti-IL17-A values for the sera of all patients without
severe CMC (a, c, d, e, f), but were lower in the serum of Patient 2 with
severe candidiasis (b)
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4,000×g for 10 min and the cell pellet was resuspended in
Krebs-Ringer phosphate buffer with dextrose (KRPD). The
density of heat-inactivated Candida was adjusted to 106/ml
with a McFarland densitometer.
Human Blood Cells
Peripheral blood mononuclear cells (PBMCs) were isolated
from the patients and controls. After density gradient centri-
fugation and removal of the mononuclear cell layer, the cells
were washed several times in KRPD. The cells were resus-
pended in Dulbecco’s modified Eagle’s Medium (DMEM;
Sigma-Aldrich, St. Louis, MO). PBMCs (5×105 cells/well)
were incubated either alone or in the presence of heat-killed
C. albicans, at 37 °C, in 96-well round-bottomed culture
plates. After 5 days of incubation, the plates were centrifuged
and the supernatants were removed and stored at −20 °C for
the determination of cytokine concentrations.
Measurement of Cytokine Concentrations
The concentrations of IL-17A, IL-17F, IL-22 and TNF-α in
the supernatants of Candida-exposed PBMCs were deter-
mined by sandwich enzyme-linked immunosorbent assays
(Quantikine, R&D Systems, MN, USA). All experiments
were performed in duplicate or triplicate.
Results
Genetic Data and Clinical Presentation
Four patients were found to be homozygous for the c.769C>T
nonsense mutation of the AIRE gene (Fig. 1a, c, and e), which
replaces the arginine codon in position 257 with a stop codon
(R257X/R257X). The parents of Patients P1, P2, and P3 and
the mother of Patient 6 were heterozygous for the mutant
allele, consistent with autosomal recessive inheritance for this
trait. Heterozygosity was also detected in a male sibling of
Patients 1 and 2 (Fig. 1a), in a brother and a sister of Patient 3
(Fig. 1c), and in one of the two brothers of Patient 6. Genomic
DNA sequencing of samples from themother and two siblings
of Patient 3 revealed a silent mutation in one allele of AIRE in
addition to the disease-causing mutation located in the other
allele (Fig. 1d).
Patients P4 and P5 carry the c.769C>T/c.1344delC com-
pound heterozygous mutation in the AIRE gene, as described
in detail elsewhere [36].
Autoantibodies Against IL-17A, IL-17F and IL-22
OD values for autoantibodies against IL-22 were higher for all
patients than for healthy controls (Fig. 2). In Patient 1, anti-IL-
22 values increased gradually between the ages of 81 and
102 months (Fig. 2a). OD values for anti-IL-22 antibodies
were slightly higher in the adult patients (Fig. 2d and e) than in
children. By contrast, the levels of anti-IL-17A autoantibodies
differed considerably between patients. These levels were
higher in Patient 2 than in the other patients. Patient 2, who
had presented CMC since the age of 18 months, had persis-
tently high anti-IL-17A levels (Fig. 2b). Patient 2 was referred
to our center at the age of 4 years, and no serum samples were
available for antibody testing before this age. Her brother, who
had no signs of CMC (Patient 1), had low or undetectable
levels of anti-IL-17A antibodies over the period of observa-
tion. Patient 3, with no signs of mucosal or skin candidiasis,
also had low or undetectable anti-IL-17A antibody levels over
a period of 4 years. Similarly, OD values for anti-IL-17A
antibodies in Patients P4, P5, and P6, who had candidiasis
of a single fingernail beginning at the age of 17 years (P5),
angular cheilitis of unknown etiology since the age of 21 years
(P6) or three short episodes of mucosal candidial disease
during the first 3 years of life (P6), were negligible, as shown
by comparison with control values and with those for Patient
2, who had prolonged, severe CMC (Fig. 2b, d–f). OD values
for IL-17Fwere intermediate, between those obtained for anti-
IL-17A and anti-IL-22 antibodies, and were not correlated
with the severity of CMC (Fig. 2a–f).
Experiments were performed to measure OD values of
anti-IL-17A and anti-IL-22 in sera of Patients 1, 2 and 3 by
using varying serum concentrations (Fig. 3). Data of these
experiments confirmed the differences in OD values found
with a single dilution of sera (Fig. 2).
Autoantibodies Against Type I Interferons
OD values for antibodies against IFN-α and IFN-ω were
measured in three patients, and were high and similar in
Patients 1 and 3 (Fig. 4). In Patient 2, with CMC, the low anti
IFN-ω antibody level contrasted with the high level of anti-
IFN-α antibodies (Fig. 4b). In Patient 3, who was followed up
from early infancy, we observed a gradual increase in the
levels of IFN-α and IFN-ω antibodies until the age of
14 months (Fig. 4c). Autoantibody production began at the
age of 7 months and sustained increases in the levels of these
antibodies resulted in high OD values later on.
Release of Cytokines by Candida-Exposed Blood Cells
We measured the release of IL-17A, IL-17F, and IL-22 by
PBMCs after 5 days of stimulation with heat-killed Candida
(Fig. 5). PBMCs from patients released negligible or small
amounts of anti-cytokine antibodies on exposure to Canadida,
compared to cells from healthy controls (Fig. 5). These data
suggest an impaired ‘Th-17-type’ response to Candida in
patients with APECED. To prove the possibility of a broader
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defect of cytokine release by Candida-exposed PBMCs, we
measured concentrations of TNF-α in supernatants as positive
control. The data of these control experiments showed that
release of TNF-α by cells from patients and controls were
comparable (Fig. 5).
Discussion
The importance of the IL-17 family of cytokines in immunity
to Candida is well established [5, 15, 19, 29, 35]. Previous
studies have suggested that anti-cytokine autoantibodies are
involved in CMC pathogenesis in APECED patients [11, 27,
28, 36]. It has been suggested that autoantibodies against
cytokines, including IL-17A, IL-17F and IL-22, may underlie
CMC in patients with APECED [11, 28]. Recent findings have
suggested that the presence of autoantibodies against IL-22
may be a useful predictor of CMC [11, 12]. It has also been
suggested that IL-17 plays a key role in protection against
Candida infection, and some patients with isolated CMC have
smaller than normal proportions of IL-17-producing T cells,
and produce only low levels of IL-17 [15, 27, 29].
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Fig. 3 Anti-IL-17A and anti-IL-22 OD values in different dilutions of
serum samples. HighOD values for anti-IL-17A antibodies were found in
each dilutions of sera from Patient 2 (P2), compared to values found in
sera of P1 and P3. In contrast, OD values of anti-IL-22 antibodies were
high in all patients with somewhat lower values found in P2 compared to
those detected in P1 and P3
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Fig. 4 Autoantibodies against IFN-α and IFN-ω in the sera of APECED patients. In Patients 1 and 3 (aand c), the OD values for both anti-IFN-α and anti-
IFN-ω antibodies were persistently high. Intriguingly, serum OD values for anti-IFN-α and anti-IFN-ω antibodies were relatively low in Patient 2 (b)
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In this study, Patient 2, with severe and prolonged CMC,
presented high levels of autoantibodies against IL-17A. The
other five patients with the same genotype or heterozygous
AIREmutation had low or undetectable anti-IL-17A antibody
levels and were asymptomatic or presented only mild and
transient signs of mucocutaneous candidiasis. Previous stud-
ies have suggested that IL-22 plays an important role in the
protection of skin and epithelial surfaces against Candida
infection [6, 39]. It has been reported that IL-22-producing
cells help to protect mucosal surfaces against fungal infection
in conditions of defective adaptive immunity, through a prim-
itive antifungal effector mechanism [6, 39]. Furthermore, IL-
22 has been reported to play a role in candidiasis, by control-
ling fungal invasion and epithelial homeostasis [39]. All six
patients included in this study had high levels of anti-IL-22
autoantibodies, but only Patient 2, with high levels of anti-IL-
17A antibodies, displayed a predisposition to severe CMC.
Furthermore, OD values for anti-IL-17F antibodies were high
in all patients, but those of Patient 2 were no higher than those
in the other patients. These findings argue against a primary
role of anti-IL-17F and anti-IL-22 antibodies in the suscepti-
bility of APECED patients to CMC, instead favoring the
concept that anti-IL17A antibodies are the primary compo-
nents of impaired anti-candidial immunity in APECED pa-
tients. Measuring functional activity of these antibodies could
have confirmed further our findings but such assays are not
currently available in our lab.
The role of anti-IFN antibodies in the pathogenesis of
disease signs in APECED patients is not fully understood.
Recent studies have shown that high levels of autoantibodies
against type I IFNs, including IFN-α and IFN-ω in particular,
are found in most patients with APECED, suggesting that
anti-IFN autoantibodies are hallmarks of the disease [10,
25]. These studies showed that autoantibodies against
IFN-ω were clearly present in all patients and that their levels
were not clearly correlated with the number or duration of
disease manifestations [17]. We found high levels of autoan-
tibodies against IFN-α in the sera of three patients studied, and
of autoantibodies against IFN-ω in Patients 1 and 3. The level
of anti-IFN-ω autoantibodies was low in Patient 2. These data
do not support the existence of a relationship between
APECED severity and anti-IFN autoantibody level. The role
of the variable levels of anti-IFN-ω antibodies in this
multiorgan primary immunodeficiency disorder therefore re-
mains to be elucidated.
Recent studies suggested that impairment of IL-17F and
IL-22 secretion by PBMC’s of APECED patients may be an
important precipitating factor in predisposition to candidiasis
[11, 23]. The role of IL-17A secretion seems somewhat con-
troversial in these studies. One of them found increased num-
bers of C. albicans-induced IL-17A-producing cells in PBMC
from APECED patients, measured by flow cytometry by
intracellular staining of IL-17A [1], in contrast with other
studies, which consistently found impaired IL-17A responses
in APECED patients [8, 11, 23]. PBMCs from our patients
released small amounts of IL-17A and much smaller, or
negligible amounts of IL-17F and IL-22 by Candida-
exposed cells, compared with healthy controls. We found
impaired secretion of IL-17A, IL-17F and IL-22 by PBMC
cells from APECED patients, with, or without severe candi-
diasis, in contrast the release of TNF-α, which was compara-
ble with healthy controls.
We provide the first description of the possible effects of
IVIG for treating severe CMC in APECED patients, and the
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Fig. 5 IL-17A, IL-17F, and IL-22 secretion by blood cells exposed to
Candida. Peripheral blood mononuclear cells were stimulated with heat-
killed Candida blastoconidia for 5 days at 37 °C. Cells were then centri-
fuged and cytokine concentration was measured in the supernatants by
ELISA, as described in “Methods”. We found impaired secretion of IL-
17A, IL-17F, and IL-22 by cells from APECED patients with or without
severe candidiasis, as shown as compared with cells from healthy controls.
In contrast, the release of TNF-α was comparable in patients and controls
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transient improvement of mucosal candidiasis following
monthly IVIG infusions in Patient 2 was intriguing. IVIG
replacement therapy is widely used to prevent infectious com-
plications in patients with primary immunodeficiency disor-
ders [13, 24]. In addition to prophylaxis, IVIG concentrates
may also be helpful for the treatment of various inflammatory
conditions [21, 33]. However, the mode of action of this
therapy in autoimmune diseases remains poorly understood.
IVIG contains anti-idiotype antibodies against disease-
associated autoantibodies [21]. These anti-idiotype antibodies
may be able to bind and neutralize the pathogenic anticytokine
antibodies typically produced by patients with APECED, con-
sistent with the decrease in autoantibody levels observed in
other conditions following IVIG therapy [32]. We believe that
IVIG treatment is unlikely to have increased the efficiency of
Candidaelimination by opsonophagocytosis, given the clinical
observation that patients with X-linked agammaglobulinemia
characterized by an almost complete lack of serum immuno-
globulins typically do not suffer from CMC or invasive
candidial disease [14]. We observed no detectable decrease in
anti-IL-17A and anti-IL-22 antibody levels IVIG therapy in
Patient 2 (data not shown), but we believe that further studies
of possible therapeutic effects of IVIG in APECED patients
with severe CMC are warranted, based on our observation.
Conclusion
We report here a correlation between anti-IL-17A autoanti-
body level and predisposition to chronic mucocutaneous can-
didiasis in APECED patients. We suggest that anti-IL-17A
autoantibodies may play a more important role than anti-IL-22
and anti-IL-17F antibodies in rendering APECED patients
susceptible to candidiasis. We suggest that high levels of
anti-IL-22 and anti-IL-17F autoantibodies may not be corre-
lated with the occurrence of candidiasis in APECED patients.
We present data suggesting that the release of IL-17A, IL-17F
and IL-22 by blood cells is impaired in APECED patients.
These data suggest that autoantibodies against cytokines may
only partly account for the susceptibility to Candida in
APECED patients. Other mechanisms may also be involved.
We suggest that IVIG substitution may be of use in APECED
patients with CMC, to lower the burden and complications of
candidiasis on body surfaces.
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